Galapagos updated their cystic fibrosis program. The significant news today, was that the company was expected to test potentiator GLPG2451 with corrector GLPG2222, from a press release on June 15th. Today, they have not made up their mind in full whether they are going to do a combination with 2451 and 2222, as potential for part of a triple combination. GLPG2451 phase 1, will have a slight delay with results in early 2017, from expected end of 2016. Thank you for reading.
No comments:
Post a Comment